SAMRATPH

Samrat Pharmachem financials

Market cap
₹65 Cr

Quarterly results

Q1 FY27: revenue up 5.4%, net profit up 482.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue70 64 71 76 79 +12%63 −0%72 +1%80 +5%
EBITDA3 4 0 0 -0 −111%-1 −116%-1 −1054%1 +585%
Net profit3 3 -0 -0 -1 −122%-0 −117%-2 −410%1 +483%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −27.8% 1Y

₹200₹250₹300Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹319.9 on 9 Sept 2025 → ₹231. High ₹327.95 (12 Sept 2025), low ₹194.95 (30 Mar 2026).

Financials, as filed

Revenue grew 1.4% a year over 2 years, FY24 to FY26. Operating margin narrowed to -0.7%.

Year endingFY24FY25FY26
Revenue₹282 Cr₹286 Cr₹290 Cr
Operating profit₹2 Cr₹10 Cr₹-2 Cr
Operating margin0.9%3.6%-0.7%
Interest₹1 Cr₹1 Cr₹1 Cr
Depreciation₹1 Cr₹1 Cr₹1 Cr
Net profit₹2 Cr₹7 Cr₹-3 Cr
Net margin0.8%2.5%-1.1%
Cash from operations₹9 Cr₹-10 Cr₹9 Cr
Free cash flow₹9 Cr₹-11 Cr₹6 Cr
ROCE3.0%13.0%-3.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr
Reserves₹27 Cr₹44 Cr₹60 Cr₹62 Cr₹68 Cr₹65 Cr
Borrowings₹9 Cr₹8 Cr₹19 Cr₹8 Cr₹11 Cr₹11 Cr
Other liabilities₹19 Cr₹30 Cr₹35 Cr₹48 Cr₹50 Cr₹46 Cr
Total liabilities₹57 Cr₹85 Cr₹117 Cr₹122 Cr₹131 Cr₹124 Cr
Fixed assets₹9 Cr₹10 Cr₹11 Cr₹11 Cr₹11 Cr₹12 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹1 Cr
Investments₹0 Cr₹0 Cr₹2 Cr₹3 Cr₹13 Cr₹4 Cr
Other assets₹48 Cr₹75 Cr₹104 Cr₹108 Cr₹107 Cr₹108 Cr
Total assets₹57 Cr₹85 Cr₹117 Cr₹122 Cr₹131 Cr₹124 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, FIIs added +3.24 pp while DIIs trimmed −3.24 pp. The shareholder count shrank 6% to 6,330.

Promoters
49.1%
FIIs
3.2%
Public
47.7%

Since Jun 2025

  • FIIs +3.24 pp
  • DIIs −3.24 pp
  • Public −0.01 pp

How it drifted, 12 quarters

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 48.6%, FIIs 3.2%, Public 48.1%.Dec '23: Promoters 48.6%, FIIs 3.2%, Public 48.1%.Mar '24: Promoters 48.6%, FIIs 3.2%, Public 48.1%.Jun '24: Promoters 48.6%, FIIs 3.2%, Public 48.1%.Sep '24: Promoters 49.0%, FIIs 3.2%, Public 47.8%.Dec '24: Promoters 49.1%, FIIs 3.2%, Public 47.7%.Mar '25: Promoters 49.1%, FIIs 3.2%, Public 47.7%.Jun '25: Promoters 49.1%, DIIs 3.2%, Public 47.7%.Sep '25: Promoters 49.1%, FIIs 3.2%, Public 47.7%.Dec '25: Promoters 49.1%, FIIs 3.2%, Public 47.7%.Mar '26: Promoters 49.1%, FIIs 3.2%, Public 47.7%.Jun '26: Promoters 49.1%, FIIs 3.2%, Public 47.7%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Samrat Pharmachem Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Lalit Damodar Mehta 13.97%unchanged
Rajesh Lalit Mehta 12.41%unchanged
Premal Lalit Mehta 5.67%unchanged
Kaushal Lalit Mehta 4.50%unchanged
Jaya Lalit Mehta 3.86%unchanged
Sangeetha S . 3.27%unchanged
Rupal Rajesh Mehta 2.66%unchanged
Falguni Kaushal Mehta 2.15%unchanged
Megh Rajesh Mehta 1.76%unchanged
Kalpana Premal Mehta 1.64%unchanged
Lalit Kumar V Jain 1.22%unchanged
Sharad Kanayalal Shah 1.13%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Samrat Pharmachem Ltd.

Guides on how to read this kind of business and the numbers that matter.